David Grayzel
InvestorManaging Director at Atlas Venture · Board director at Xilio Therapeutics · Board director at Affinia Therapeutics
Cambridge, Massachusetts, United States
Writes $500K – $5M checks · typically $2M
Find your path to David
255 people in our graph share verified history with David — schools, employers, funds. One of them is your warm intro.
About
David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).
Contact· self-published, not guessed
Invests in
BiotechHealthtech
Board director at Xilio Therapeutics
Intro paths
In turn, David can intro founders to Xilio Therapeutics's investors below.
Xilio Therapeutics's investors · 16
Co-founders at Xilio Therapeutics
Board director at Affinia Therapeutics
Intro paths
In turn, David can intro founders to Affinia Therapeutics's investors below.
Affinia Therapeutics's investors · 8
Co-founders at Affinia Therapeutics
Experience
- Atlas VenturePartnercurrent2014 — presentCambridge, MA
- Atlas Venture Development Corp.Managing Directorcurrent2010 — present
- Infinity PharmaceuticalsVP Clinical Development and Medical Affairs2002 — 2010
- Dyax CorpDirector Corporate Development and Business Operations2000 — 2002
- Massachusetts General HospitalIntern, Resident1997 — 2000
Deals · 4
Triana Biomedicines, Inc.Board seat
via Atlas Venture · filed Dec 2025 · $120.1M raise
Xilio TherapeuticsBoard seat
via Atlas Venture · filed Feb 2021 · $95M raise
Aerovate Therapeutics, Inc.Board seat
via Atlas Venture · filed Aug 2020 · $75.8M raise
Akriveia TherapeuticsBoard seat
via Atlas Venture · filed Jan 2018 · $22.5M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
AerovateAffinia TherapeuticsAffinia TherapeuticsAnnovation BiopharmaArteaus TherapeuticsCadent TherapeuticsComanche BiopharmaComanche BiopharmaDay One BiopharmaceuticalsDeliniaQ32 BioSurface OncologyTrace NeuroscienceTRIANA BiomedicinesVima Therapeutics
Investor
Affinia TherapeuticsComanche BiopharmaDeliniaQ32 BioTrace NeuroscienceTriana BiomedicinesVima Therapeutics, Inc.
Sources: the firm's website · SEC Form D filings · curated public sources.
Colleagues at Atlas Venture
Network5
Investors connected to David in public investor directories — a warm-intro map.
Frequently asked questions
- Who is David Grayzel?
- David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).
- Where does David Grayzel work?
- David Grayzel is Managing Director at Atlas Venture and Board director at Xilio Therapeutics and Board director at Affinia Therapeutics.
- What does David Grayzel invest in?
- David Grayzel invests in Biotech, Healthtech.
- What check size does David Grayzel write?
- David Grayzel typically writes checks of $500K – $5M.
- What boards does David Grayzel sit on?
- David Grayzel holds tracked board seats at Aerovate, Aerovate Therapeutics, Inc., Affinia Therapeutics, Affinia Therapeutics, Akriveia Therapeutics, Annovation Biopharma, Arteaus Therapeutics, Cadent Therapeutics, Comanche Biopharma, Comanche Biopharma.
- What companies has David Grayzel invested in?
- Investments tracked here include Affinia Therapeutics, Comanche Biopharma, Delinia, Q32 Bio, Trace Neuroscience, Triana Biomedicines, Vima Therapeutics, Inc..
- Where did David Grayzel go to school?
- David Grayzel studied at Harvard Medical School (MD); Stanford University (BA).
Same school
Also attended Harvard Medical School328
+ 322 more
Also attended Stanford University2,000
+ 1,994 more
Shared employers
Also worked at Infinity Pharmaceuticals11
+ 5 more
Also worked at Dyax Corp5
Also worked at Massachusetts General Hospital129
+ 123 more